Stringent criteria for withdrawal of biologics in ulcerative colitis
Lancet Gastroenterol Hepatol
.
2021 Sep;6(9):687-688.
doi: 10.1016/S2468-1253(21)00181-3.
Authors
Malcolm Tan
1
,
Valerie Ng
2
,
Chong Teik Lim
3
,
Wei-Qiang Leow
4
,
Webber Chan
3
Affiliations
1
Department of Gastroenterology and Hepatology, Singapore General Hospital, 169608, Singapore. Electronic address: malcolm.tan.t.k@singhealth.com.sg.
2
Department of Pharmacy, Singapore General Hospital, 169608, Singapore.
3
Department of Gastroenterology and Hepatology, Singapore General Hospital, 169608, Singapore.
4
Department of Anatomical Pathology, Singapore General Hospital, 169608, Singapore.
PMID:
34391517
DOI:
10.1016/S2468-1253(21)00181-3
No abstract available
Publication types
Letter
Comment
MeSH terms
Biological Factors
Biological Products* / adverse effects
Colitis, Ulcerative* / drug therapy
Humans
Substances
Biological Factors
Biological Products